[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342516-105":59,"doc-detail-342516-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","machine-learning-based-extrachromosomal-dna-identification-in-large-scale-cohorts-reveals-its-clinical-implications-in-cancer","Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer","","Extrachromosomal DNA (ecDNA) remains poorly understood in cancer therapy, despite its emerging role as a cancer hallmark. The study performs a comprehensive pan-cancer analysis of ecDNA amplification spectra across cohorts exceeding 13,000 patients, using a computational framework (GCAP) with multifaceted validation. Results show consistent mutual exclusivity between ecDNA amplification and microsatellite instability, refined colorectal subtypes, and biomarker value for anti-PD-1 checkpoint blockade in gastrointestinal cancer from four clinical trials. Overall, ecDNA amplification is demonstrated as a WES-based proof-of-concept for personalized treatment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/machine-learning-based-extrachromosomal-dna-identification-in-large-scale-cohorts-reveals-its-clinical-implications-in-cancer/342516/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/machine-learning-based-extrachromosomal-dna-identification-in-large-scale-cohorts-reveals-its-clinical-implications-in-cancer/342516.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main clinical gap the study addresses about ecDNA?","Question",{"text":112,"@type":113},"The clinical implications of extrachromosomal DNA (ecDNA) in cancer therapy remain largely elusive.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does GCAP contribute to the ecDNA analysis?",{"text":117,"@type":113},"GCAP is a computational framework used to analyze ecDNA amplification spectra and to reveal associations with clinical and molecular features, validated through multiple approaches.",{"name":119,"@type":110,"acceptedAnswer":120},"What biomarker relationship does the study report for immunotherapy?",{"text":121,"@type":113},"EcDNA amplification is identified as a biomarker for guiding anti-PD-1 checkpoint blockade immunotherapy in gastrointestinal cancer, linking ecDNA amplification to immunotherapy effectiveness.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342516,1790223089,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Article [https://doi.org/10.1038/s41467-024-45479-6](https://doi.org/10.1038/s41467-024-45479-6)  \nMachine learning-based extrachromosomal DNA identiﬁcation in large-scale cohorts reveals its clinical implications in cancer  \nReceived: 4 July 2023  \n\n| Accepted: 24 January 2024 |\n| --- |\n| |\n| Check for updates |\n\nShixiang Wang 1,3, Chen-Yi Wu1,3, Ming-Ming He1,3, Jia-Xin Yong1,3, Yan-Xing Chen1, Li-Mei Qian1, Jin-Ling Zhang1, Zhao-Lei Zeng 1, Rui-Hua Xu 1,2,4 , Feng Wang 1,4  & Qi Zhao 1,4   \nThe clinical implications of extrachromosomal DNA (ecDNA) in cancer therapy remain largely elusive. Here, we present a comprehensive analysis of ecDNA ampliﬁcation spectra and their association with clinical and molecular features in multiple cohorts comprising over 13,000 pan-cancer patients. Using our developed computational framework, GCAP, and validating it with multifaceted approaches, we reveal a consistent pan-cancer pattern of mutual exclusivity between ecDNA ampliﬁcation and microsatellite instability(MSI). In addition, we establish theroleofecDNA ampliﬁcation asa risk factor andreﬁne genomic subtypes in a cohort from 1015 colorectal cancer patients. Importantly, our investigation incorporates data from four clinical trials focused on anti-PD-1 immunotherapy, demonstrating the pivotal role of ecDNA ampliﬁcation as a biomarker for guiding checkpoint blockade immunotherapy in gastrointestinal cancer. This ﬁnding represents clinical evidence linking ecDNA ampliﬁcation to the effectiveness of immunotherapeutic interventions. Overall, our study provides a proof-of-concept of identifying ecDNA ampliﬁcation from cancer whole-exome sequencing (WES) data, highlighting the potential of ecDNA ampliﬁcation as a valuable biomarker for facilitating personalized cancer treatment.  \nExtrachromosomal DNA (ecDNA) was ﬁrst observed in 19651,2, however, its critical role as an emerging cancer hallmark is only recently coming forth with the advancements in technology3. EcDNAs, circular DNA elements with 1 Mb size on average, exhibiting unique properties4,5 such as cancer-speciﬁc molecules of non-Mendelian inheritance, high chromatin accessibility, and clustered mutations. Lines of effort have been made to delineate the physical structure of ecDNA, and how ecDNA could lead to oncogene ampliﬁcation, active transcription as well as the ability to change tumor genomes rapidly  \nand dynamically6–12. By these traits, ecDNA relieves heredity constraints, fuels tumor evolution and intra-tumor heterogeneity to make cancer more adaptable to tumor microenvironment13,14. As an important form of somatic focal copy number ampliﬁcation, ecDNA ampliﬁcation has been discovered as a prevalent event that drives aggressive tumor growth, multi-drug resistance and poor survival outcomes across widespread cancer types15–17. These ﬁndings suggest the potential of ecDNA as a molecular marker for cancer diagnosis and a drug target for cancer treatment. Nevertheless, clinically feasible  \n1State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. 2Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou 510060, China. 3These authors contributed equally: Shixiang Wang, Chen-Yi Wu, Ming-Ming He, Jia-Xin Yong. 4These authors jointly supervised this work: Rui-Hua Xu, Feng Wang, Qi Zhao. e-mail: [xurh@sysucc.org.cn](xurh@sysucc.org.cn);  \n[wangfeng@sysucc.org.cn](wangfeng@sysucc.org.cn); [zhaoqi@sysucc.org.cn](zhaoqi@sysucc.org.cn)  \napproaches for identifying ecDNA ampliﬁcation that rely on accessible, supportive high-throughput cancer genome data are still lacking, and the clinical relevance of ecDNA in either common heterogeneous malignances (e.g., colorectal cancer (CRC)) or in advanced therapy context (e.g., checkpoint blo","cbCaipVtuQZRZeGt","https://ap.wps.com/l/cbCaipVtuQZRZeGt","pdf",3193010,17,"English","# Background\n## Clinical implications of ecDNA\n# Methods\n## Computational framework (GCAP)\n## Sequencing and targeted approaches\n# Results\n## Pan-cancer mutual exclusivity with MSI\n## Colorectal cancer subtypes via ecDNA amplification\n## Biomarker role in anti-PD-1 trials","[{\"question\":\"What is the main clinical gap the study addresses about ecDNA?\",\"answer\":\"The clinical implications of extrachromosomal DNA (ecDNA) in cancer therapy remain largely elusive.\"},{\"question\":\"How does GCAP contribute to the ecDNA analysis?\",\"answer\":\"GCAP is a computational framework used to analyze ecDNA amplification spectra and to reveal associations with clinical and molecular features, validated through multiple approaches.\"},{\"question\":\"What biomarker relationship does the study report for immunotherapy?\",\"answer\":\"EcDNA amplification is identified as a biomarker for guiding anti-PD-1 checkpoint blockade immunotherapy in gastrointestinal cancer, linking ecDNA amplification to immunotherapy effectiveness.\"}]","Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer | PDF",1790046935,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37ddbb78721f212df7ff39a2139c59b2.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61868dcfdd7607c3b340c1e4a5c5cc7a.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f6df0805ad9e0ce51e42a10985a83da.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6b48e50d8c0130ff842ee469b916bdc.webp",980,1301]